Impact of Pre-PCI Activated Clotting Time on Outcomes of Bivalirudin Versus Heparin During Primary PCI.

ABSTRACT:

Background

The BRIGHT-4 trial demonstrated that procedural anticoagulation with bivalirudin followed by a median 3-hour high-dose infusion reduced the 30-day composite of all-cause mortality or Bleeding Academic Research Consortium (BARC) types 3 to 5 bleeding compared with heparin alone among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Whether the pre-PCI activated clotting time (ACT) influences this benefit is unknown. In the study, we aim to investigate whether the pre-PCI ACT levels affected the outcomes with each anticoagulant.

Methods

The BRIGHT-4 protocol required a pre-PCI ACT to be assessed 5 minutes after study medications were administered with additional anticoagulant boluses given to achie

SUBMITTER: Liu M 

PROVIDER: S-EPMC12485531 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature